For doses greater than 45.6 GyE, the 2-year local control rate was 58 % and the
overall survival rate was 54 %, both of which are higher than in the low-dose group
Yamada S: NIRS-Med-Austron Meeting 2013
NIRS: Locally Advanced Pancreatic Cancer